Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic agonists of TLR9
    Patent number: 7884197
    Abstract: The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: February 8, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Dong Yu, Lakshmi Bhagat, Daqing Wang, Sudhir Agrawal
  • Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
    Patent number: 7875594
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: January 25, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshmi Bhagat, Dong Yu
  • OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS
    Publication number: 20110009477
    Abstract: The invention provides novel oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif and the use of such compounds in the prevention and treatment of TLR-medicated diseases. These oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif have one or more chemical modifications in the immune stimulatory motif, which would be immune stimulatory but for the modification.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Dong Yu, Lakshmi Bhagat, Daqing Wang, Ekambar Kandimalla, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Patent number: 7863250
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: January 4, 2011
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • METHODS AND COMPOSITONS FOR ANTISENSE VEGF OLIGONUCLEOTIDES
    Publication number: 20100330152
    Abstract: This invention relates to compositions and methods for inhibition of abnormal proliferation of cells or angiogenesis. More particularly this invention provides VEGF antisense oligonucleotides capable of inhibiting proliferation of cancer cells or angiogenesis or combinations thereof. also provided are screening and prognostic assays, as well kits comprising the VEGF antisense oligonucleotides.
    Type: Application
    Filed: October 5, 2009
    Publication date: December 30, 2010
    Applicant: VasGene Therapeutics, Inc.
    Inventors: Parkash Gill, Rizwan Masood, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Patent number: 7851453
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: December 14, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar R. Kandimalla
  • Short immunomodulatory oligonucleotides
    Patent number: 7851454
    Abstract: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred embodiments, cause immune stimulation across species lines.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: December 14, 2010
    Assignee: Idera Pharmaceutials, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7833538
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: November 16, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7824696
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5? ends
    Patent number: 7812000
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: October 12, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends
    Publication number: 20100254974
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: January 27, 2010
    Publication date: October 7, 2010
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7790168
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: September 7, 2010
    Assignee: Idera Pharmaceuticals, Inc
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments
    Patent number: 7786089
    Abstract: The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: August 31, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • IMMUNOSTIMULATORY ACTIVITY OF PALINDROMIC IMMUNE MODULATORY OLIGONUCLEOTIDES (IMO) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS
    Publication number: 20100215646
    Abstract: The invention provides a palindromic immune modulatory nucleic acid.
    Type: Application
    Filed: May 5, 2010
    Publication date: August 26, 2010
    Inventors: Ekambar R. Kandimalla, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • SYNTHETIC RNA-BASED AGONISTS OF TLR7
    Publication number: 20100215642
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.
    Type: Application
    Filed: February 10, 2010
    Publication date: August 26, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Tao Lan, Ekambar Kandimalla, Daqing Wang, Sudhir Agrawal
  • Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
    Patent number: 7776834
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: August 17, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar Kandimalla
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5? ends
    Patent number: 7749975
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: July 6, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • IMMUNOSTIMULATORY OLIGONUCLEOTIDE MULTIMERS
    Publication number: 20100166736
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: September 23, 2009
    Publication date: July 1, 2010
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Publication number: 20100166805
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: December 3, 2009
    Publication date: July 1, 2010
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar Kandimalla
  • IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS COMPRISING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
    Publication number: 20100143328
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: October 21, 2008
    Publication date: June 10, 2010
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar R. Kandimalla